Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses

BACKGROUND: PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships between patient characteristics, prior lines of therapy, dose intensity, and dose modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Cesne, Axel Le, Bauer, Sebastian, Demetri, George D., Han, Guangyang, Dezzani, Luca, Ahmad, Qasim, Blay, Jean-Yves, Judson, Ian, Schöffski, Patrick, Aglietta, Massimo, Hohenberger, Peter, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691522/
https://www.ncbi.nlm.nih.gov/pubmed/31409302
http://dx.doi.org/10.1186/s12885-019-5988-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691522/
https://www.ncbi.nlm.nih.gov/pubmed/31409302
http://dx.doi.org/10.1186/s12885-019-5988-3

Ejemplares similares